论文部分内容阅读
目的探讨米非司酮在子宫肌瘤合并贫血术前预处理中的价值,为子宫肌瘤合并贫血临床治疗提供理论依据。方法将子宫肌瘤合并中重度贫血患者80例根据随机数字表法分为观察组和对照组,每组各40例,对照组直接行输血处理,完毕后再行手术治疗;观察组给予米非司酮与琥珀酸亚铁联合用药治疗。比较两组患者的临床疗效、手术情况、血红蛋白水平变化、雌激素水平变化及不良反应情况。结果观察组治疗后的血红蛋白水平显著高于治疗前与对照组同期(P<0.05),而对照组治疗前后的血红蛋白水平比较差异无统计学意义(P>0.05)。与治疗前相比,两组患者治疗后的各项雌激素水平均有显著降低,其中观察组的降低幅度较对照组更为显著(P<0.05)。观察组患者的手术出血量显著少于对照组,手术操作时间、住院时间显著短于对照组,医疗花费显著低于对照组(P<0.05);观察组患者治疗后的总有效率95%,显著高于对照组的80%,差异有统计学意义(P<0.05);观察组不良反应发生率5.0%;与对照组的7.5%比较,无显著差异。结论子宫肌瘤伴贫血患者术前应用米非司酮有助于纠正患者的贫血症状,提高补血效果,降低手术创伤与医疗花费。
Objective To investigate the value of mifepristone in preoperative treatment of uterine fibroids with anemia, and to provide a theoretical basis for clinical treatment of uterine fibroids with anemia. Methods 80 patients with uterine fibroids combined with moderate to severe anemia were divided into observation group and control group according to random number table method, 40 cases in each group. The control group was transfused directly and then operated by surgery. Division ketones and ferrous succinate combination therapy. The clinical efficacy, operative conditions, hemoglobin level changes, estrogen levels and adverse reactions were compared between the two groups. Results The hemoglobin level of the observation group was significantly higher than that of the control group before treatment (P <0.05), while there was no significant difference in the hemoglobin level before and after treatment in the control group (P> 0.05). Compared with those before treatment, the levels of estrogen in both groups were significantly decreased after treatment, and the decrease in observation group was more significant than that in control group (P <0.05). The patients in the observation group had less operation bleeding, the operation time and hospital stay were significantly shorter than those in the control group, and the medical expenses were significantly lower than those in the control group (P <0.05). The total effective rate in the observation group was 95% Which was significantly higher than 80% of the control group (P <0.05). The incidence of adverse reactions in the observation group was 5.0%. Compared with the control group, 7.5%, there was no significant difference. Conclusion The application of mifepristone in patients with uterine fibroids and anemia before operation can help to correct the symptoms of anemia in patients and improve the effect of blood supplement and reduce the cost of surgical trauma and medical treatment.